← All trials
NCT00734435
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2008
- Primary completion
- Dec 1, 2008
- Completion date
- Dec 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Orexigen Therapeutics, IncLead sponsor
- Larue D. Carter HospitalOverall official - principal investigator
- American Medical ResearchOverall official - principal investigator
- Brooklyn Medical InstituteOverall official - principal investigator
- Synergy ResearchOverall official - principal investigator
- Atlanta Center for Medical ResearchOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
- CNRI-LA, Pico Rivera CAOverall official - principal investigator
- Florida Clinical Research Center, LLCOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.